United States · FDA National Drug Code directory
Naropin
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 63323-285_324532ac-4e54-4659-a1a2-9ade22a1ed3f
- Product NDC
- 63323-285
- Form
- INJECTION, SOLUTION
- Composition / generic term
- ROPIVACAINE HYDROCHLORIDE
- Labeler
- Fresenius Kabi USA, LLC
- Marketing category
- NDA
- Marketing start / end (source format)
- 20090804
- Source listing expiry
- 20261231
Source-listed ingredients
- ROPIVACAINE HYDROCHLORIDE — 2 mg/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 25 VIAL, SINGLE-USE in 1 CARTON (63323-285-28) / 20 mL in 1 VIAL, SINGLE-USE (63323-285-41) · 63323-285-28
- 12 BOTTLE in 1 CASE (63323-285-68) / 100 mL in 1 BOTTLE (63323-285-53) · 63323-285-68
- 12 BOTTLE in 1 CASE (63323-285-73) / 200 mL in 1 BOTTLE (63323-285-59) · 63323-285-73
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →